Allergan PLC is selling its women's health and infectious disease businesses after completing its strategic review, CNBC reported, citing sources familiar with the matter.
The Dublin-based company was reportedly weighing the sale of its women's health unit in April following confirmation that the company was undergoing a strategic review process.
The Botox maker evaluated transactions including share repurchases, selling certain business units, splitting the company, entering M&A deals and continuing its current business strategy to create shareholder value.
"We have a strong view both of our women's health and anti-infectives business, but they are less strategically important," Allergan's Chairman, President and CEO Brent Saunders previously said in the company's first-quarter 2018 earnings call.
Analysts from Cowen valued the business at $4 billion, while the infectious disease unit is at $2 billion.
